1-5 of 5
Bjørn Tore Gjertsen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT066: Dendritic cell based cryoimmunotherapy associates with clinical variables and changes in T-cell receptor expression in a prospective phase I trial of metastatic castration resistant prostate cancer

Free
Liv Cecilie V. Thomsen, Alfred Honorè, Bjarte Almås, Lars A. Reisæter, Jannicke Frugård, Einar K. Kristoffersen, Guro Melve, Torjan Haslerud, Jarle Rørvik, Martin Biermann, Svein Inge Helle, Gunnar Kvalheim, Waqas Azeem, Jan Roger Olsen, Ole Johan Halvorsen, Lars Akslen, Duke K. Bahn, Klaus Pantel, Sabine Riethdorf, Haakon Ragde, Bjørn Tore Gjertsen, Anne M. Øyan, Karl-Henning Kalland, Christian Beisland
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT066.
https://doi.org/10.1158/1538-7445.AM2018-CT066
Published: 01 July 2018
View articletitled, Abstract CT066: Dendritic cell based cryoimmunotherapy associates with clinical variables and changes in T-cell receptor expression in a prospective phase I trial of metastatic castration resistant prostate cancer
Journal Articles

Abstract CT056: A Phase Ib/II randomised open label study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib compared to pembrolizumab or dabrafenib/trametinib alone, in patients with advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanoma

Free
Oddbjorn Straume, Cornelia Schuster, James Lorens, Bjørn Tore Gjertsen
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT056.
https://doi.org/10.1158/1538-7445.AM2017-CT056
Published: 01 July 2017
View articletitled, Abstract CT056: A Phase Ib/II randomised open label study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib compared to pembrolizumab or dabrafenib/trametinib alone, in patients with advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanoma
Journal Articles

Abstract 3274: Combination of elacytarabine and daunorubicin is significantly more effective than combination of cytarabine and daunorubicin in primary patient xenografts of AML.

Free
Tereza Osdal, Lars P. Jordheim, Mihaela Popa, Lene M. Vikebø, Andre Sulen, Siv Lise Bedringaas, Marit Liland Sandvold, Birgitte Booij, Øystein Bruserud, Bjørn Tore Gjertsen, Charles Dumontet, Emmet McCormack
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 3274.
https://doi.org/10.1158/1538-7445.AM2013-3274
Published: 15 April 2013
View articletitled, Abstract 3274: Combination of elacytarabine and daunorubicin is significantly more effective than combination of cytarabine and daunorubicin in primary patient xenografts of AML.
Journal Articles

Nitroreductase, a Near-Infrared Reporter Platform for In Vivo Time-Domain Optical Imaging of Metastatic Cancer

Free
Emmet McCormack, Elisabeth Silden, Richard M. West, Tina Pavlin, David R. Micklem, James B. Lorens, Bengt Erik Haug, Michael E. Cooper, Bjørn Tore Gjertsen
Journal: Cancer Research
Cancer Res (2013) 73 (4): 1276–1286.
https://doi.org/10.1158/0008-5472.CAN-12-2649
Published: 14 February 2013
View articletitled, Nitroreductase, a Near-Infrared Reporter Platform for In Vivo Time-Domain Optical Imaging of Metastatic Cancer
Open the PDF for Nitroreductase, a Near-Infrared Reporter Platform for In Vivo Time-Domain Optical Imaging of Metastatic Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 3308: Axl is required for EMT-induced stem cell traits and metastasis in breast cancer

Free
Crina Tiron, Ingunn Stefansson, Hallvard Haugen, Tone Sandal, Emmet McCormack, Bjørn Tore Gjertsen, David Micklem, Johanna Ivaska, Lars Akslen, James Lorens
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3308.
https://doi.org/10.1158/1538-7445.AM2012-3308
Published: 15 April 2012
View articletitled, Abstract 3308: Axl is required for EMT-induced stem cell traits and metastasis in breast cancer